DJ Hardman & Co Research on International Biotechnology Trust (IBT): Industry M&A remains a key driver
Hardman & Co Research
Hardman & Co Research on International Biotechnology Trust (IBT): Industry M&A remains a key driver
10-Jul-2023 / 10:40 GMT/BST
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Hardman & Co Research on International Biotechnology Trust (IBT):
Industry M&A remains a key driver
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global
biotechnology and life science companies, from venture-stage early drug discovery via venture capital funds (SV Health
Investors) through to global, multinational biotechnology companies. The trust's main aim is to generate capital
growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the past five
years, IBT's NAV per share has increased 37%, while the share price has risen 36% in the same period - differentiated
returns are generally due to changes in the share price discount.
Please click on the link below for the full report:
https://hardmanandco.com/research/corporate-research/industry-ma-remains-a-key-driver/
If you are interested in meeting the company, you can register your interest by clicking on the above link
To contact us:
Hardman & Co Contact:
1 Frederick's Place
Martin Hall
London mh@hardmanandco.com
EC2R 8AE
+44(0)203 693 7075
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
1676289 10-Jul-2023
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1676289&application_name=news
(END) Dow Jones Newswires
July 10, 2023 05:40 ET (09:40 GMT)
